Maryland State Retirement & Pension System Has $521,000 Stock Position in Enovis Corporation $ENOV

Maryland State Retirement & Pension System lessened its stake in Enovis Corporation (NYSE:ENOV) by 13.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,627 shares of the company’s stock after selling 2,588 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Enovis were worth $521,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of ENOV. Vanguard Group Inc. raised its stake in Enovis by 11.3% in the first quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock valued at $233,356,000 after purchasing an additional 621,069 shares in the last quarter. Invenomic Capital Management LP grew its position in Enovis by 199.6% in the first quarter. Invenomic Capital Management LP now owns 449,777 shares of the company’s stock valued at $17,186,000 after acquiring an additional 299,658 shares during the last quarter. DAVENPORT & Co LLC grew its position in Enovis by 10.4% in the first quarter. DAVENPORT & Co LLC now owns 3,071,985 shares of the company’s stock valued at $116,489,000 after acquiring an additional 289,644 shares during the last quarter. Paradigm Capital Management Inc. NY grew its position in Enovis by 47.5% in the first quarter. Paradigm Capital Management Inc. NY now owns 786,400 shares of the company’s stock valued at $30,048,000 after acquiring an additional 253,200 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in Enovis by 734.5% in the first quarter. Victory Capital Management Inc. now owns 275,058 shares of the company’s stock valued at $10,510,000 after acquiring an additional 242,096 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Insider Transactions at Enovis

In other news, SVP Bradley J. Tandy bought 3,200 shares of the stock in a transaction dated Friday, August 22nd. The shares were bought at an average cost of $31.41 per share, with a total value of $100,512.00. Following the completion of the transaction, the senior vice president directly owned 43,515 shares of the company’s stock, valued at $1,366,806.15. This trade represents a 7.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Damien Mcdonald bought 6,457 shares of the stock in a transaction dated Thursday, September 11th. The shares were purchased at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the transaction, the chief executive officer directly owned 102,753 shares of the company’s stock, valued at $3,182,260.41. This trade represents a 6.71% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 12,157 shares of company stock valued at $374,760 over the last ninety days. 2.70% of the stock is owned by company insiders.

Enovis Price Performance

Shares of ENOV opened at $29.76 on Tuesday. Enovis Corporation has a 52-week low of $25.47 and a 52-week high of $49.83. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25. The business’s 50 day moving average price is $30.56 and its two-hundred day moving average price is $31.68. The firm has a market cap of $1.70 billion, a PE ratio of -2.09 and a beta of 1.69.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The firm had revenue of $383.81 million for the quarter. On average, equities analysts anticipate that Enovis Corporation will post 2.79 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ENOV shares. Evercore ISI decreased their target price on Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Canaccord Genuity Group reduced their price target on Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a report on Wednesday, October 8th. Needham & Company LLC reduced their price target on Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Finally, UBS Group reduced their price target on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $51.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.